entertainment -WSS

entertainment

author：focus 2025-10-01 18:23:50 - browse：49

Adam's take main illustration — Molly Ferguson/STAT

Anavex Life Sciences is in a tough spot. The serial dissembler of clinical trial results might be forced, finally, to tell the truth when it reads out its next study in Rett syndrome.

What sets Anavex apart from all the other biotechs on my radar screen is its habit of shifting the goalposts on clinical trials. Twice last year, first in February and then in December, Anavex announced “positive” outcomes from studies of its drug called blarcamesine — except the results were derived from efficacy endpoints that were not part of the original study designs.

If blarcamesine fails to achieve the pre-determined goals of clinical trials, the thinking apparently goes, then just make a post-hoc change to the study goals.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Medtronic CEO on promising devices for diabetes, hypertension

WSS

Paying for Covid pills will soon shift to insurers

Emergency medicine has repudiated 'excited delirium.' Now what?

Paying for Covid pills will soon shift to insurers

Telehealth options flood the market as retailers push virtual care

Bird flu outbreak in cows is latest avian flu curveball

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

knowledge

entertainment

Wikipedia

BioMarin wins approval for gene therapy to treat hemophilia A

UnitedHealth financials solid despite Change Healthcare cyberattack

Apple is now the first public company to be valued at $3 trillion

Eli Lilly to pay $200M for Beam’s stake in gene

At least 13 dead in Texas as scorching temps continue

The pink breast cancer awareness ribbon needs a redesign

The high cost of giving birth even with insurance

Meta's Zuckerberg and Chan on track to put $50 billion into science

As demand for Covid shots wanes, Moderna seeks its next success

Emergency medicine has repudiated 'excited delirium.' Now what?

focus

Emergency medicine has repudiated 'excited delirium.' Now what?

MassMutual is introducing free genetic testing for members

Key Senate committee drafts bipartisan bill to stem drug shortages

First Opinion Podcast: How to protect health care in times of war

Traditional Chinese medicine benefits explored in new JAMA study

CDC recommends rationing of RSV shot due to shortages

knowledge

focus

knowledge

hotspot